SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob −/− mice

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown ...

Source: Cardiovascular Diabetology - February 7, 2019 Category: Cardiology Authors: Damilola D. Adingupu, Sven O. G öpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan and Ann-Cathrine Jönsson-Rylander Tags: Original investigation Source Type: research